Tan et al. have shown that the level of ErbB2 in tamoxifen-resistant ER+ breast cancer is tightly regulated by interplay between miR-26a/b and human antigen R (HuR) (Fig. 2) [95]. Here, ERBB2 is linked to breast cancer.